Dasatinib + Quercetin: The First Clinically Proven Senolytic Combination
Expert Summary
The D+Q protocol stands as the single most evidence-backed senolytic intervention in human medicine. The Xu et al. (2018) Nature Medicine paper demonstrated: measurable reduction in p16+p21-positive senescent cells in adipose tissue biopsies, reduction in circulating SASP factors (IL-6, MMP-3, MMP-9), and improvement in physical function (walking speed, chair stand, stair climbing) in patients with idiopathic pulmonary fibrosis.
Key Facts
Mechanism synergy: Dasatinib inhibits ephrin receptors and src-family kinase survival signals specifically upregulated in senescent epithelial cells. Quercetin inhibits BCL-2/BCL-XL and PI3K/AKT specifically upregulated in senescent adipocytes. Together, they cover two distinct senescent cell survival pathways.
Pilot study design: 9 patients with IPF (a fibrotic lung disease strongly linked to cellular senescence). Dasatinib 100 mg + quercetin 1,000 mg oral × 3 days over a 3-week period. Open-label, no placebo control.
Biomarker results: p16INK4A mRNA in skin: -67%. p21: -25%. Circulating MMP-3: -27%. MMP-9: -37%. IL-6: -40%. These are the most specific senolytic biomarkers available in human studies.
Physical function: Gait speed +50%. 4-meter walk test improved significantly. Chair stand count improved. These functional improvements in a debilitating disease are clinically meaningful.
Subsequent trials: Multiple Phase 2 trials have followed: diabetic kidney disease (DKD), Alzheimer's, frailty in older adults. All report consistent senescent cell reduction and functional improvements.
Protocol frequency in longevity use: For healthy aging (not disease), most longevity physicians recommend quarterly cycles: dasatinib 100 mg + quercetin 1,000 mg for 2 consecutive days every 3 months.
Frequently Asked Questions
How do I access dasatinib for longevity purposes?
Dasatinib is a prescription medication (Sprycel®, Bristol-Myers Squibb). In most countries, prescription requires physician evaluation. Longevity medicine practitioners, internists, and some gerontologists may prescribe it off-label for aging indications. Aging.ai and similar directories list longevity physicians.
What monitoring is required with D+Q?
CBC (platelet count monitoring for thrombocytopenia risk), liver function tests, and cardiac evaluation (ECG for QTc prolongation) are standard pre-treatment assessments. Repeat CBC after the first cycle is recommended.
Is D+Q safe for people without disease?
The safety profile of intermittent D+Q (2–3 days per quarter) in healthy aging individuals appears favorable, but no large safety trial has been conducted in this population specifically. The risk-benefit calculation favors caution without physician oversight.
Get the free Longevity Supplement Starter Guide
Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.
Scientific References
Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130
Hickson LJ et al. Senolytics decrease senescent cells in humans. EBioMedicine. 2019. PMID: 31542391